Timothy E. Morris has been a member of DBV’s Board of Directors since 2021. He served as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. Mr. Morris previously served on the Board of Directors of Humanigen as an Independent Director and Chairman of the Audit Committee from July 2016 to July 2020. He currently serves on the Board of Humanigen Australia Pty Ltd, Humanigen Ltd (UK) and Humanigen Europe Ltd, all wholly owned subsidiaries of Humanigen, Inc. Mr. Morris has 36 years of professional finance and accounting experience, including 22 years as Chief Financial Officer with public biotechnology companies (IOVA, ACRX, VVUS, QCOR). During his career he has raised over $2.2 billion in equity and convertible securities for seven companies, including four offerings for IOVA with over $1 billion in proceeds. Prior to Humanigen, Mr. Morris was CFO at Iovance where he oversaw an increase in market cap from $550 million to $4.2 billion (7x increase). He has extensive deal experience with 90 transactions and combined value in excess of $4.8 billion. Mr. Morris has been part of executive teams that were successful in the approval of 3 NDAs and 1 MAA. He is a CPA (inactive) and started his career from Chico State with Ernst & Young in Silicon Valley.